TLSA News

Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab

Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab

Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer